Sign inJoin waitlistJoin the waitlist

Tareq Abuasab

Assistant Professor · Baylor College of Medicine

Credentials: · ·

History

Baylor College of Medicine
Present

Shaare Zedek Medical Center
2024–2025
Internal Medicine
2021–2024
Doctor of Medicine
2007–2011

Research

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
The Lancet Haematology · 2024 · 25 citations
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
JCO Oncology Practice · 2024 · 9 citations
Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
Review · Biologics · 2021 · First of 3 authors · 6 citations

GB
Gautam Borthakur
8 papers
Hagop Kantarjian
8 papers
Courtney DiNardo
7 papers
Tapan Kadia
7 papers
Guillermo Garcia-Manero
6 papers
Nicholas Short
6 papers
Elias Jabbour
5 papers
KS
Koji Sasaki
5 papers
Naval Daver
5 papers
Naveen Pemmaraju
4 papers
Sanam Loghavi
4 papers
Alexandre Bazinet
3 papers · 3 as a fellow

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2031